Modafinil 200 mg is a prescription medicine used in the UK to treat excessive daytime sleepiness, mainly in conditions such as narcolepsy, obstructive sleep apnoea (when sleepiness persists despite treatment), and sometimes shift work sleep disorder.
Modafinil is a wakefulness-promoting agent, not a traditional stimulant. It works by affecting brain chemicals involved in alertness, including dopamine and orexin pathways, helping patients stay awake and improve daytime functioning without the intense “rush” associated with amphetamine-like stimulants.
In UK clinical practice, the 200 mg dose is the most commonly prescribed adult dose, usually taken once daily in the morning or before a work shift. Some patients may start on a lower dose (100 mg) and increase to 200 mg depending on response and tolerability.
Clinical studies show that modafinil can significantly reduce daytime sleepiness and improve alertness, attention, and quality of life in people with diagnosed sleep disorders. However, it is not a general energy enhancer and is not recommended for treating ordinary fatigue or lack of sleep.
In the UK, modafinil is classified as a prescription-only medicine (POM) and is strictly regulated. It is also sometimes misused off-label for cognitive enhancement, but this is not medically approved and is discouraged due to potential risks.
Common side effects include headache, nausea, anxiety, insomnia, and dizziness. Rare but serious risks include skin reactions and cardiovascular effects, so medical supervision is essential.
UK guidance emphasises that modafinil should be used only when a clear diagnosis exists and as part of a broader treatment plan that may include sleep hygiene and management of underlying sleep disorders.
👍 Conclusion
Modafinil 200 mg is an effective UK-prescribed treatment for excessive daytime sleepiness caused by specific medical conditions. While it improves alertness and functioning, it is tightly regulated and should only be used under specialist supervision due to potential side effects and misuse concerns.